Welsh GP contract 2025/26

Read about the outcome of tripartite negotiations for the Welsh GMS contract, which covers 2025/26 and investment for 2026/27. 

Location: Wales
Audience: GPs
Updated: Friday 12 December 2025
GP practice article illustration

Following extensive negotiations, GPC Wales has reached an agreement for the GMS contract with Welsh Government and NHS Wales. The final deal, covering the current 2025-26 financial year and elements of 2026-27, was announced by the Cabinet Secretary for Health and Social Care. 

This year’s talks were much delayed due to budget uncertainty, with the initial government funding offer falling short of our costed requirements. 

We threatened a formal contract dispute, and to begin preparations for a collective action ballot, prompting assurances from the Cabinet Secretary of a multi-year strategy and an improved funding settlement. On this basis, negotiations continued. The resulting outcome will see a £41.9m investment for 2025-26, and a guaranteed recurrent uplift of 5.8% to the contract for 2026-27. This provides practices with stability and certainty ahead of the Senedd Cymru elections in May 2026.
 

This agreement builds on the momentum from last year’s contract referendum, where you told Welsh Government that the status quo was not good enough. This resulted in an improved offer, albeit one with non-recurrent funding elements. The investment from this negotiation round is entirely recurrent - and would not have been possible without a mobilised profession. 

A GMS Contract Implementation Group will meet to take forward the immediate outcomes, facilitate their implementation into the GMS contract and produce detailed guidance for practices. The contractual guidance will be published in due course alongside the Statement of Financial Entitlements on the Welsh Government website. 

Furthermore, a range of working groups will be established to take forward the commitments for 2026-27 and beyond, including the ‘Community by Design’ transformation programme, and scoping a review of the global sum funding allocation formula. We will produced detailed advice for practices on these areas as work progresses over the coming months. 

Financial changes

The table details the recurrent investment stemming from this contract agreement 

The 2025-26 funding is made on a recurrent basis, will be backdated to April 2025, and is equivalent to approx. 9% of the total contract value. 

It includes a guaranteed 5.8% funding uplift from the start of the 2026-27 financial year, with the value of investment to be recurrent. It is intended to give practices the certainty to play a fundamental role in the wider NHS Wales transformation programme. This 2026-27 uplift is separate from the usual consideration by Welsh Government of the recommendations of the DDRB for 2026. 



Contractual changes (immediate)

Area Comment
Funding
  • Pay and expenses uplifts as detailed. New global sum = £134.15 per weighted patient

  • Commitment to a review of Global Sum Allocation Formula: to be scoped through a tripartite group.

  • Population Adjustment: total contract value will be uplifted according to the latest available figures.
    QI and supplementary services
    • Projects agreed for 25/26 and in circulation.

    • QIF point value for 25/26 uplifted by 4% = £206.96 per point

    • No uplift in Directed Supplementary Service values this year.

    • Commitment to a group to review DSS specs and pricing.
      Data and Digital
      • Patients will have access to a summary patient record including allergies, immunisations and health conditions (excluding free text and test results) via the NHS Wales App.

      • Subject to agreement on processes, this will be rolled out before the end of March 2026.
        SFE reimbursements
        • 24.1% uplift to SFE reimbursement entitlements for Parental and Sick leave cover. New rates:

        • Parental: £1,418.34 per week (first two weeks); £2,151.96 per week (week 3 onward)

        • Sickness: £2,151.96 per week (week 3 onward)

        • Suspended doctor: £2,151.96 per week

        • Independent prescriber cover rates will be paid at 62.2% of the GP rates.
          Partnership Premium
          • 10.5% uplift to Partnership Premium rates. New rates:

          • Base rate: £1,105/session

          • Rate for >16 years: £1,316/session

          • No change in seniority scheme
            High risk and chronic disease patients
            • Maintain registers for "high risk frailty patients" (quarterly) and "inclusion health" (annual).

            • Structured medication review: new question added to CGP-SAT but no expectation of process change.

            • Diabetes eight care processes: automated sharing with Health Boards of aggregate practice data only.
              Additional Capacity Fund Continuation of the previous 50:50 matched funding process for 25/26



              QIF

              The Quality and Improvement Framework (QIF) is made up of two domains, Access and Quality Improvement.  The QIF points value has always applied to both access and quality improvement.  We have agreed to uplift the points value by 4% to ensure value preservation. The QIF points value will therefore increase from £199 to £206.96 backdated to 1 April 2025.  

              There are no changes to the Quality Improvement projects for 2025-26, which were agreed earlier this year and already underway: 

              • Chronic Kidney Disease (CKD) - 70 points

              • Improving Cardiovascular Outcomes – 70 points

              • Continuity of Care – 30 points 

              Transformation agenda

              As per the Cabinet Secretary’s correspondence, the 5.8% ringfenced uplift to GMS contract is intended to “provide practices with the certainty needed to invest in the necessary resources to enable GPs to play a fundamental role in the transformation programme.”.  

              This refers to the ‘Community by Design’ transformation work being led by the Chief Medical Officer, with GPC Wales as a key partner. The ongoing Directed Collaborative Services discussions, which were part of the 2024/25 agreement, in theory will provide the practice-led structures for the resourced ‘Shift Left’ of services. 

              The funding will be recurrent to GMS from April 2026 and is estimated at around £30m, based on 5.8% of the total GMS contract value. The exact uplift figure will be calculated based on the GMS allocation at end March 2026 

              It has been clarified that this investment is additional and unrelated to any pay and expenses award in 2026-27, which would follow the consideration by the Welsh Government (pre- or post-2026 Senedd elections) of the DDRB’s recommendations. 

              The uplift is to be split equally across three elements:  

              Workforce Fund = £14m (including £4m from Additional Capacity Fund (AFC))

              • 100% reimbursement for workforce, to be held by Health Boards with similar mechanism to ACF but without any matched requirement. 

                Allocation will be based on raw population list size.

              Change Fund = £10m

              • Funding to meet practice costs for transformation related to delivery of Directed Collaborative Services. To be held by Health boards with claiming mechanism. 

                Allocation will be based on raw population list size.

              Resilience Fund = £10m 

              • This will be invested directly into the Global Sum and distributed through the GSum Allocation formula. 

              We acknowledge concerns that funding held by Health Boards may be in danger of being reallocated to other budget lines beyond GMS. As a result, we have agreed a mechanism for a GMS Residual payment. Any underspend from either Workforce or Change funds at a defined point in the year will be paid out to practices (based on raw list size redistribution) within that Health Board at the conclusion of the financial year. 

              Commitments ahead for 26-27

              We have made a number of commitments that will be progressed via working groups, outlined in Table 3. The outputs of these groups would be brought back to the Contract Reform Group or will inform future negotiations. These are: 

              Area Comment
              Access Review the future of access standards ahead of potential implementation from Apr 2026.
              Funding Scoping and commissioning review of the Global Sum Allocation Formula.
              QI and supplementary services
              • Group to look at equity of access to supplementary services.

              • Work on Directed Collaborative Services model (part of 2024/25 agreement) to continue.
                Data and digital Consider technical and safety implications of wider NHS Wales App functionality: authorised access, test results in summary care record, e-triage, non-urgent appointment booking.
                Dispensing Continue dispensing reform working group with intent to produce recommendations to inform 2027-28 negotiations.
                High risk and chronic disease patients Explore mainstreaming All Wales Diabetes Prevention Programme from Apr 2026
                Premises
                • Continue T&F group work on new Premises Cost Directions

                • Review and map current arrangements for Branch and secondary sites
                  Vaccinations and immunisations Extended scoping work with SSP/WG policy team to uprate Item of Service fees.
                  Protected Learning Time Recommend consistent funding approach across all HBs